Scientists may have just discovered that one of the world’s most talked-about medications has a remarkable hidden benefit. A major new study published in The Lancet Psychiatry has found that GLP-1 medications like semaglutide — the active ingredient in Ozempic, Wegovy, and Rybelsus — are associated with dramatic reductions in depression, anxiety, and substance use disorders. Researchers from the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia analyzed data from nearly 100,000 individuals tracked through Swedish national health registers over more than a decade. The findings were striking: during periods when participants were taking semaglutide, psychiatric-related hospital visits and sickness absence dropped by 42% compared to periods without the drug. The risk of depression was 44% lower, anxiety disorders were reduced by 38%, and hospital care related to substance use disorders fell by 47%.
The research team notes that while the exact mechanism isn’t yet fully understood, the associations were far stronger than expected. Scientists suspect a combination of factors could be at play — improvements in body image from weight loss, better blood sugar control for diabetes patients, reduced alcohol consumption, and potentially direct effects on the brain’s reward system. “Because this is a registry-based study, we cannot determine exactly why or how these medications affect mood symptoms, but the association was quite strong,” said Research Director Markku Lähteenvuo from the University of Eastern Finland. While more research is needed to fully confirm the link, the study adds to a growing body of evidence that GLP-1 medications that are already celebrated for their impact on obesity, diabetes and heart health, may be quietly reshaping how we think about mental health treatment as well.
Source: https://www.sciencedaily.com/releases/2026/03/260322020250.htm
